Find A Clinical Trial

Disease Type: Multiple Hematologic

Trial ID 22087
Sponsor ID H3B-8800-G000-101

“An Open-label, Multicenter Phase 1 Trial to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of Splicing Modulator H3B-8800 for Subjects With Myelodysplastic Syndromes, Acute Myeloid Leukemia, and Chronic Myelomonocytic Leukemia (H3B-8800-G000-101)”

Principal Investigator
Mitul Gandhi, MD
Trial ID 21328
Sponsor ID KCP-8602-801

“A PHASE 1/2 OPEN-LABEL STUDY OF THE SAFETY, TOLERABILITY AND EFFICACY OF THE SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) COMPOUND ELTANEXOR (KPT-8602) IN PATIENTS WITH NEWLY DIAGNOSED AND RELAPSED/REFRACTORY CANCER INDICATIONS (KCP-8602-801)”

Principal Investigator
Mitul Gandhi, MD
Trial ID ERAS-007-04
Sponsor ID HERKULES-4

A Phase 1b/2 Master Protocol of Agents Targeting the Mitogen-Activated Protein Kinase Pathway in Patients with Hematologic Malignancies (HERKULES-4).

Trial ID 21469
Sponsor ID LOTIS 9

A Phase 2 open-label study of loncastuximab tesirine in combination with rituximab (Lonca-R) in previously untreated unfit/frail patients with diffuse large B-cell lymphoma (DLBCL) (LOTIS-9/ ADCT-402-203)

Principal Investigator
Mitul Gandhi, MD
Trial ID 21356
Sponsor ID Genentech

AN OPEN-LABEL, MULTICENTER, PHASE II TRIAL EVALUATING THE SAFETY, EFFICACY, AND PHARMACOKINETICS OF SUBCUTANEOUS MOSUNETUZUMAB MONOTHERAPY IN PATIENTS WITH SELECT B-CELL MALIGNANCIES (ML43389)

Principal Investigator
Mitul Gandhi, MD
Trial ID SET-101
Sponsor ID Epizyme, Inc.

A Phase 1/1b, Open-Label Multi Center Two Part Study of SETD2 Inhibitor EZM414 in Subjects with Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Trial ID M20-178
Sponsor ID TRANSFORM-2

A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination with Ruxolitinib Versus Best Available Therapy in Subjects with Relapsed/Refractory Myelofibrosis

Principal Investigator
Mitul Gandhi, MD
Trial ID 20346
Sponsor ID XPORT-MF-035

A Phase 2, Randomized, Open-Label, Multicenter Study to Evaluate Safety and Efficacy of Single Agent Selinexor Versus Treatment of Physician’s Choice in Patients with Previously Treated Myelofibrosis

Principal Investigator
Mitul Gandhi, MD